May 16, 2018: On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib. Collaboration marks first therapy submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial. Click here for more details.
April 24, 2018: Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria!
A new study published in The Journal of the American Medical Association (JAMA) brings new hope and optimism to the Progeria community. Click here for more details.